arrow
F

Frank A. Sinicrope

case western reserve university
H指数:77
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201
2026-01-010
OA
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors

MSI-High结直肠癌患者接受免疫检查点抑制剂治疗后BRAF V600E突变对预后的影响

2025-07-120
PRE
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study

早期结直肠癌患者基因组突变模式:一项国际、多队列、观察性研究

2025-07-030
PRE
BRAF plus EGFR plus /- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer

BRAF V600E突变和错配修复缺陷或微卫星不稳定性高转移性结直肠癌免疫检查点抑制剂后BRAF加EGFR加/- MEK抑制剂

2024-10-012
PRE
Impact of RAS and BRAFV600E mutations on tumor immune microenvironment and associated genomic alterations in patients with microsatellite instability (MSI) or DNA mismatch repair deficient (dMMR) colorectal cancers

RAS和 BRAFV600E 突变对微卫星不稳定(MSI)或DNA错配修复缺陷(dMMR)结直肠癌患者肿瘤免疫微环境及相关基因组改变的影响

2024-09-011
PRE
Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
2024-06-010
PRE
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting
2024-01-014
PRE